Search clinical trials for: HS-10296

Total 213 results

Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Nonsmall Cell Lung Cancer

United States
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Sun Yat-sen University

Not yet recruiting

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). (AERESA)

Lung Cancer

China
West China Hospital

Recruiting

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Non-small Cell Lung Cancer

China
First People's Hospital of Hangzhou

Not yet recruiting

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Brain Metastases | EGFR Positive Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
Shanghai Chest Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (ACTIVE)

Lung Cancer | EGFR Gene Mutation
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

EGFR-mutant Non-Small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Non Small Cell Lung Cancer

China
Shanghai Chest Hospital

Not yet recruiting

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (ATTACK)

NSCLC
Concert Pharmaceuticals

Completed

Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz

Healthy Volunteers
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in T2DM Participants

Type 2 Diabetes

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383

Cough

China
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study of HS-10353 in Chinese Participants.

Major Depressive Disorder

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression

Treatment Resistant Depressive Disorder

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383

Cough

China
Qingdao Sino-Cell Biomedicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; West China... and other collaborators

Recruiting

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

Cough
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction

Healthy

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase 1a Study in Healthy Participants

Healthy
Heartseed Inc.

Recruiting

A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) (LAPiS)

Heart Failure | Ischemic Heart Disease

Japan
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia (HS-25-III-01)

Primary Hypercholesterolemia
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial of HS-10511 in Healthy Subjects

Hypertrophic Cardiomyopathy
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10518 in Healthy Female Participants

Endometriosis
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10517 in Chinese Adult Participants

COVID-19

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10353 in Adult Participants With Major Depressive Disorder

Major Depressive Disorder (MDD)
Hansoh BioMedical R&D Company

Recruiting

Study of HS-10384 in Participants of Chinese Postmenopausal Women

Vasomotor Symptoms

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Overweight and Obesity

China
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study (SIMPLIFY-HS)

Cystic Fibrosis

United States
Heat Biologics

Completed

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

Advanced Solid Tumor

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in Healthy Participants

Type 2 Diabetes

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Psoriasis

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostatic Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Herbert Lyerly

Terminated

A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

Solid Tumor

United States
HeadSense Medical
Rigshospitalet, Denmark

Unknown

Comparison of the Non-invasive ICP HeadSense Monitor vs Lumbar CSF Pressure Measurement

Intracranial Hypertension

Denmark, Germany, Netherlands
HeadSense Medical
State Medical Center, Republic of Armenia

Completed

An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Routine Care

Stroke

Armenia
Shanghai Hansoh Biomedical Co., Ltd

Recruiting

A Study of HS-20089 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma
Hansoh BioMedical R&D Company

Recruiting

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Sarcoma | Osteosarcoma

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Advanced Non-Small-Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Solid Tumor

China

3

Subscribe